Evidence map›Paper›PMID 30018230›Full record

ArticleMolecules (Basel, Switzerland)2018

Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal

Scott M Baliban, Jessica C Allen, Brittany Curtis, Mohammed N Amin, Andrew Lees, R Nageswara Rao, Gangadhara Naidu, Ramasamy Venkatesan, D Yogeswara Rao, Vadrevu Krishna Mohan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Prevalence and distribution of non-typhoidalEpidemiology and infection · 2023
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Multivalent vaccines for invasiveInfection and immunity · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Foodborne Infections andVaccines · 2024
    Review
  10. Article
  11. Article
  12. Open forum infectious diseases · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Preclinical evaluation of OMVs as potential vaccine candidates againstFrontiers in cellular and infection microbiology · 2022
    Article
  17. Review
  18. Pathogenic signature of invasive non-typhoidalHuman vaccines & immunotherapeutics · 2020
    Review
  19. Overview of the Nontyphoidal and Paratyphoidal Salmonella Vaccine Pipeline: Current Status and Future Prospects.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Review
  20. Surveillance for Invasive Salmonella Disease in Bamako, Mali, From 2002 to 2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Scott M BalibanCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. sbaliban@som.umaryland.edu.
Jessica C AllenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. jessica.allen@umaryland.edu.
Brittany CurtisCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. bcurtis1@som.umaryland.edu.
Mohammed N AminCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. mamin@som.umaryland.edu.
Andrew LeesFina Biosolutions LLC, 9430 Key West Ave. Suite 200, Rockville, MD 20850, USA. alees@finabio.com.
R Nageswara RaoBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. rnrao55@yahoo.com.
Gangadhara NaiduBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. gangadhara1975@bharatbiotech.com.
Ramasamy VenkatesanBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. venkatesanr@bharatbiotech.com.
D Yogeswara RaoBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. yogeswar.danda@bharatbiotech.com.
Vadrevu Krishna MohanBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. kmohan@bharatbiotech.com.
Krishna M EllaBharat Biotech International Limited, Hyderabad 500 078, Telangana, India. ella@bharatbiotech.com.
Myron M LevineCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. mlevine@som.umaryland.edu.
Raphael SimonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. rsimon@som.umaryland.edu.
Bharat Biotech (India) · INUniversity of Maryland, Baltimore · USEmergent BioSolutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Typhoid fever due to

Indexed as

GlycoconjugatesImmunogenicity, VaccineSalmonella typhiTyphoid FeverTyphoid-Paratyphoid VaccinesAnimalsAntibodies, BacterialRabbitsAntibodies, BacterialGlycoconjugatesTyphoid-Paratyphoid VaccinesantibodyflagellinglycoconjugateiNTSlipopolysaccharideSalmonellatyphoidvaccineVi

Identifiers

PMID30018230
PMCPMC6099966
OpenAlexW2884459088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.